A stagewise response to mitochondrial dysfunction in mitochondrial DNA maintenance disorders
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
Mitochondrial DNA (mtDNA) deletions which clonally expand in skeletal muscle of patients with mtDNA maintenance disorders, impair mitochondrial oxidative phosphorylation dysfunction. Previously we have shown that these mtDNA deletions arise and accumulate in perinuclear mitochondria causing localised mitochondrial dysfunction before spreading through the muscle fibre. We believe that mito-nuclear signalling is a key contributor in the accumulation and spread of mtDNA deletions, and that knowledge of how muscle fibres respond to mitochondrial dysfunction is key to our understanding of disease mechanisms. To understand the contribution of mito-nuclear signalling to the spread of mitochondrial dysfunction, we use imaging mass cytometry. We characterise the levels of mitochondrial Oxidative Phosphorylation proteins alongside a mitochondrial mass marker, in a cohort of patients with mtDNA maintenance disorders. Our expanded panel included protein markers of key signalling pathways, allowing us to investigate cellular responses to different combinations of oxidative phosphorylation dysfunction and ragged red fibres. We find combined Complex I and IV deficiency to be most common. Interestingly, in fibres deficient for one or more complexes, the remaining complexes are often upregulated beyond the increase of mitochondrial mass typically observed in ragged red fibres. We further find that oxidative phosphorylation deficient fibres exhibit an increase in the abundance of proteins involved in proteostasis, e.g. HSP60 and LONP1, and regulation of mitochondrial metabolism (including oxidative phosphorylation and proteolysis, e.g. PHB1). Our analysis suggests that the cellular response to mitochondrial dysfunction changes depending on the combination of deficient oxidative phosphorylation complexes in each fibre.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1870 |
|---|---|
| Enthalten in: |
Biochimica et biophysica acta. Molecular basis of disease - 1870(2024), 5 vom: 21. März, Seite 167131 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vincent, Amy E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cell signalling |
|---|
| Anmerkungen: |
Date Revised 05.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.bbadis.2024.167131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370109813 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370109813 | ||
| 003 | DE-627 | ||
| 005 | 20240406232352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbadis.2024.167131 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1367.xml |
| 035 | |a (DE-627)NLM370109813 | ||
| 035 | |a (NLM)38521420 | ||
| 035 | |a (PII)S0925-4439(24)00120-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vincent, Amy E |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A stagewise response to mitochondrial dysfunction in mitochondrial DNA maintenance disorders |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Mitochondrial DNA (mtDNA) deletions which clonally expand in skeletal muscle of patients with mtDNA maintenance disorders, impair mitochondrial oxidative phosphorylation dysfunction. Previously we have shown that these mtDNA deletions arise and accumulate in perinuclear mitochondria causing localised mitochondrial dysfunction before spreading through the muscle fibre. We believe that mito-nuclear signalling is a key contributor in the accumulation and spread of mtDNA deletions, and that knowledge of how muscle fibres respond to mitochondrial dysfunction is key to our understanding of disease mechanisms. To understand the contribution of mito-nuclear signalling to the spread of mitochondrial dysfunction, we use imaging mass cytometry. We characterise the levels of mitochondrial Oxidative Phosphorylation proteins alongside a mitochondrial mass marker, in a cohort of patients with mtDNA maintenance disorders. Our expanded panel included protein markers of key signalling pathways, allowing us to investigate cellular responses to different combinations of oxidative phosphorylation dysfunction and ragged red fibres. We find combined Complex I and IV deficiency to be most common. Interestingly, in fibres deficient for one or more complexes, the remaining complexes are often upregulated beyond the increase of mitochondrial mass typically observed in ragged red fibres. We further find that oxidative phosphorylation deficient fibres exhibit an increase in the abundance of proteins involved in proteostasis, e.g. HSP60 and LONP1, and regulation of mitochondrial metabolism (including oxidative phosphorylation and proteolysis, e.g. PHB1). Our analysis suggests that the cellular response to mitochondrial dysfunction changes depending on the combination of deficient oxidative phosphorylation complexes in each fibre | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell signalling | |
| 650 | 4 | |a Mitochondrial DNA deletion | |
| 650 | 4 | |a Mitochondrial disease | |
| 650 | 4 | |a Myopathy | |
| 650 | 4 | |a OXPHOS | |
| 700 | 1 | |a Chen, Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, Tiago Bernardino |e verfasserin |4 aut | |
| 700 | 1 | |a Di Leo, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Laalo, Tuomas |e verfasserin |4 aut | |
| 700 | 1 | |a Pabis, Kamil |e verfasserin |4 aut | |
| 700 | 1 | |a Capaldi, Rodrick |e verfasserin |4 aut | |
| 700 | 1 | |a Marusich, Michael F |e verfasserin |4 aut | |
| 700 | 1 | |a McDonald, David |e verfasserin |4 aut | |
| 700 | 1 | |a Filby, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Fuller, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Lehmann Urban, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Zierz, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Deschauer, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Turnbull, Doug |e verfasserin |4 aut | |
| 700 | 1 | |a Reeve, Amy K |e verfasserin |4 aut | |
| 700 | 1 | |a Lawless, Conor |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochimica et biophysica acta. Molecular basis of disease |d 2017 |g 1870(2024), 5 vom: 21. März, Seite 167131 |w (DE-627)NLM260137588 |x 1879-260X |7 nnns |
| 773 | 1 | 8 | |g volume:1870 |g year:2024 |g number:5 |g day:21 |g month:03 |g pages:167131 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbadis.2024.167131 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1870 |j 2024 |e 5 |b 21 |c 03 |h 167131 | ||